Cost-effectiveness analysis of four clinical therapeutic schemes for the first lime with vulvovaginal candidiasis
- VernacularTitle:抗真菌药物治疗初发外阴阴道假丝酵母菌病的成本-效果分析
- Author:
Chunfen WU
;
Xiaoli QIN
- Publication Type:Journal Article
- Keywords:
Vulvovaginitis;
Pseudomonas infections;
Economics,pharmaeeutieal;
Cost-benefit analysis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2008;15(6):979-981
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of four therapeutic regimes in the treatment of pa-tients with initial vulvovaginal eandidiasis. Methods 160 patients who were found for the first time with vulvovagi-hal eandidiasis were divided into four groups randomly: group A is clotrimazole (500rag) vaginal tablets; group B is fluconazole eaptica;group C is clotrimazole vaginal tablets combined with flueonazole;group D is nystatin vaginal ef-fervescent tablets. Date was evaluated using clinic economies co,t-effectiveness analysis. Results Among four groups,the costs for group A,B,C and D were 167.20 yuan, 190.23 yuan,237.43 ynan and 216.40 yuan,respec-tively. The tatol effective rates were 90.88 %, 90.12 %, 91.67 % and 67.10 %, respectively. The cost-effectiveness ratio were 1.84,2.11,2.59 and 3.23, respectively. The incremental cost-effectiveness ratios of group B, C and D vs group A were 32.90,87.78 and 2.07. Conclusion Regime A was superior than the other therapeutic regimes.
